|本期目录/Table of Contents|

[1]王伟远,刘丹丹,张蓓,等.类风湿关节炎患者血清14-3-3η蛋白水平及临床检测价值的初步研究[J].天津医科大学学报,2022,28(01):95.
 WANG Wei-yuan,LIU Dan-dan,ZHANG Bei,et al.Preliminary study on serum 14-3-3η protein level and clinical detection value in patients with rheumatoid arthritis[J].Journal of Tianjin Medical University,2022,28(01):95.
点击复制

类风湿关节炎患者血清14-3-3η蛋白水平及临床检测价值的初步研究(PDF)
分享到:

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
28卷
期数:
2022年01期
页码:
95
栏目:
临床研究
出版日期:
2022-01-20

文章信息/Info

Title:
Preliminary study on serum 14-3-3η protein level and clinical detection value in patients with rheumatoid arthritis
文章编号:
1006-8147(2022)01-0095-05
作者:
王伟远12刘丹丹1张蓓1蔡悦3薄娜娜2雷洁2李会强1
(1.天津医科大学医学检验学院,天津300203;2.天津中医药大学第一附属医院检验科,天津 300193;3.天津中医药大学第一附属医院风湿免疫科, 天津 300193)
Author(s):
WANG Wei-yuan12LIU Dan-dan1ZHANG Bei1CAI Yue3BO Na-na2LEI Jie2LI Hui-qiang1
(1.School of Medical Laboratory, Tianjin Medical University, Tianjin 300203,China;2.Clinical Laboratory,The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine,Tianjin 300193,China;3.Department of Rheumatology,The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine,Tianjin 300193,China)
关键词:
类风湿关节炎血清14-3-3η蛋白抗CCP抗体 D-二聚体类风湿因子
Keywords:
rheumatoid arthritisserum14-3-3η protein anti-CCP antibody D-Dimer rheumatoid factor
分类号:
R593.22
DOI:
-
文献标志码:
A
摘要:
目的:定量测定类风湿关节炎(RA)患者血清14-3-3η蛋白表达水平并探讨其临床检测价值。方法:收集2020年5月—2020年12月在天津中医药大学第一附属医院就诊的136例RA患者(RA组)、65例非RA关节病变患者(疾病对照组)及同期36名健康体检者(健康对照组)作为研究对象,采用光激化学发光法检测所有研究对象的血清14-3-3η水平,酶联免疫法检测抗环瓜氨酸肽抗体(anti-CCP)水平,免疫比浊法检测D-二聚体(D-Dimer)水平,散射比浊法检测类风湿因子(RF)、C反应蛋白(CRP)水平,分析以上指标在不同组间的表达差异以及指标间的相关性。结果:根据14-3-3η水平将RA组分为14-3-3η阳性组与14-3-3η阴性组,阳性组66例,阴性组70例。RA组血清14-3-3η水平显著高于疾病对照组、健康对照组(U=40.5、0.0,均P<0.000 1);14-3-3η阳性组14-3-3η蛋白与DAS28-CRP评分(DAS28-CRP)、RF呈正相关(r=0.259 8,P<0.05;r=0.248 0,P<0.05);与红细胞沉降率(ESR)、D-Dimer呈负相关(r=-0.235 4,P<0.05;r=-0.253 6,P<0.05.);14-3-3η阳性组RF与anti-CCP的表达均显著高于14-3-3η阴性组(U=758,P=0.000;U=528,P=0.006)。结论:血清14-3-3η蛋白在部分RA患者血清中呈高浓度,且与RF水平以及临床疾病活动度密切相关。
Abstract:
Objective: To quantify the concentration of serum 14-3-3η protein in patients with rheumatoid arthritis(RA) and to explore its clinical value. Methods: A total of 136 cases of RA patients(RA group),65 cases of non-RA joint disease patients(disease control group) and 36 cases of healthy individuals(healthy control group) in the First Teaching Hospital of Tianjin University of Traditional Chinese Medicine from May 2020 to December 2020 were collected. The serum 14-3-3η levels of all subjects were detected by the light-induced chemiluminescence method.The anti-CCP levels were detected by the enzyme-linked immunosorbent method,the D-Dimer levels were detected by the immunoturbidimetric method, and the levels of RF and CRP were detected by the scattering turbidimetric method.Furthermore, the expression differences among three groups and the correlations of those biomarkers mentioned above were analyzed. Results: The RA group was divided into 14-3-3η positive group and 14-3-3η negative group according to the serum level of 14-3-3η, with 66 cases in the positive group and 70 cases in the negative group.The serum 14-3-3η level in RA group was significantly higher than that of disease control group and healthy control group(U=40.5, U=0.0,all P<0.000 1).The serum 14-3-3η level in14-3-3η positive group was positively correlated with DAS28-CRP and rheumatoid factor(RF)(r=0.259 8,0.248 0, all P<0.05)and negatively correlated with ESR,D-Dimer(r=-0.235 4,-0.253 6,all P<0.05). The expression of both RF and anti-CCP were significantly higher in the 14-3-3 η positive group than those in 14-3-3η negative group(U=758,P=0.000;U=528,P=0.006,respectively). Conclusion: Serum 14-3-3η protein concentration is highly concentrated in serum of some patients with RA, and is closely related to RF level and clinical disease activity.

参考文献/References:

[1] SMOLEN J S,ALETAHA D,MCINNES I B. Rheumatoid arthritis[J]. Lancet,2016,388(10055):2023-2038.
[2] ALETAHA D,NEOGI T,SILMAN A J,et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative[J]. Arthritis Rheum,2010,62(9):2569-2581.
[3] CHANG P Y,YANG C T,CHENG C H,et al. Diagnostic performance of anti-cyclic citrullinated peptide and rheumatoid factor in patients with rheumatoid arthritis[J]. Int J Rheum Dis,2016,19(9):880-886.
[4] KILANI R T,MAKSYMOWYCH W P,AITKEN A,et al. Detection of high levels of 2 specific isoforms of 14-3-3 proteins in synovial fluid from patients with joint inflammation[J]. J Rheumatol,2007,34(8):1650-1657.
[5] MAKSYMOWYCH W P,VAN DER HEIJDE D,ALLAART C F,et al. 14-3-3eta is a novel mediator associated with the pathogenesis of rheumatoid arthritis and joint damage[J]. Arthritis Res Ther,2014,16(2):R99.
[6] RUDWALEIT M,VAN DER HEIJDE D,LANDEWE R,et al. The development of Assessment of Spondylo Arthritis International Society classification criteria for axial spondyloarthritis(part Ⅱ): validation and final selection[J]. Ann Rheum Dis,2009,68(6):777-783.
[7] ZHANG W,DOHERTY M,LEEB B F,et al. EULAR evidence-based recommendations for the diagnosis of hand osteoarthritis: report of a task force of ESCISIT[J]. Ann Rheum Dis,2009,68(1):8-17.
[8] MEWAR D ,WILSON A G. Autoantibodies in rheumatoid arthritis: a review[J]. Biomed Pharmacother,2006,60(10):648-655.
[9] MAKSYMOWYCH W P,BOIRE G,VAN SCHAARDENBURG D,et al. 14-3-3eta Autoantibodies: diagnostic use in early rheumatoid arthritis[J]. J Rheumatol,2015,42(9):1587-1594.
[10] WANG Y,PEI F,WANG X,et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody for juvenile idiopathic arthritis[J]. J Immunol Res,2015,2015:915276.
[11] CARRIER N,MAROTTA A,DE BRUM-FERNANDES A J,et al. Serum levels of 14-3-3eta protein supplement C-reactive protein and rheumatoid arthritis-associated antibodies to predict clinical and radiographic outcomes in a prospective cohort of patients with recent-onset inflammatory polyarthritis[J]. Arthritis Res Ther,2016, 18:37.
[12] SHOVMAN O,GILBURD B,WATAD A,et al. Decrease in 14-3-3eta protein levels is correlated with improvement in disease activity in patients with rheumatoid arthritis treated with Tofacitinib[J]. Pharmacol Res,2019,141:623-626.
[13] ZENG T,TAN L,WU Y,et al. 14-3-3eta Protein in rheumatoid arthritis: promising diagnostic marker and independent risk factor for osteoporosis[J]. Lab Med,2020,51(5):529-539.
[14] HAMMAM N,SALAH S,KHOLEF E F,et al. 14-3-3eta Protein in serum and synovial fluid correlates with radiographic damage and progression in a longitudinal evaluation of patients with established rheumatoid arthritis[J]. Mod Rheumatol,2020,30(4):664-670.
[15] TU J,CHEN X,DAI M,et al. Serum levels of 14-3-3eta are associated with increased disease risk,activity and duration of rheumatoid arthritis in Chinese patients[J]. Exp Ther Med,2020,20(2):754-761.
[16] HAMMAM N,GAMAL N M,ELZOHRI M H,et al. Serum 14-3-3eta protein is associated with clinical and serologic features of Sjogren′s syndrome in patients with systemic lupus erythematosus:a cross-sectional analysis[J]. Clin Rheumatol,2020,39(9):2603-2610.
[17] HIRATA S,MAROTTA A,GUI Y,et al. Serum 14-3-3eta level is associated with severity and clinical outcomes of rheumatoid arthritis,and its pretreatment level is predictive of DAS28 remission with tocilizumab[J]. Arthritis Res Ther,2015,17:280.

相似文献/References:

[1]明建松,王晓雪,杨梦晨,等.MiR-145-5p对胶原诱导的关节炎小鼠关节炎症的影响[J].天津医科大学学报,2019,25(02):115.
 MING Jian-song,WANG Xiao-xue,YANG Meng-chen,et al.Effects of miR-145-5p on joint inflammation in collagen-induced arthritis mice[J].Journal of Tianjin Medical University,2019,25(01):115.
[2]刘 勤,张学军,岳 超.中性粒细胞与淋巴细胞比值在类风湿关节炎诊断中的价值分析[J].天津医科大学学报,2019,25(04):366.
 LIU Qin,ZHANG Xue-jun,YUE Chao.Value of the ratio of neutrophil to lymphocyte in the diagnosis of rheumatoid arthritis[J].Journal of Tianjin Medical University,2019,25(01):366.
[3]岳 超,刘 勤,白 虹.联合检测抗CCP、RF、抗RA33在类风湿关节炎的临床应用[J].天津医科大学学报,2020,26(01):68.
 YUE Chao,LIU Qin,BAI Hong.Joint detection of anti-CCP, RF and anti-RA33 in rheumatoid arthritis clinical application[J].Journal of Tianjin Medical University,2020,26(01):68.
[4]赵妍,赵晶晶,刘爱芬,等.基于网络药理学探讨托法替布联合甲氨蝶呤治疗 类风湿关节炎的作用机制[J].天津医科大学学报,2022,28(03):272.
 ZHAO Yan,ZHAO Jing-jing,LIU Ai-fen,et al.Systematic elaboration of the mechanism of tofacitinib combined with methotrexate in the treatment of rheumatoid arthritis via network pharmacology[J].Journal of Tianjin Medical University,2022,28(01):272.

备注/Memo

备注/Memo:
作者简介 王伟远(1988-),男,主管技师,硕士在读,研究方向:类风湿关节炎实验室诊断;通信作者:李会强,E-mail:lihuiqiang1965@163.com。
更新日期/Last Update: 2022-01-20